Parametric Portfolio Associates LLC Buys Shares of 9,549 Evolent Health, Inc (NYSE:EVH)

Parametric Portfolio Associates LLC purchased a new position in Evolent Health, Inc (NYSE:EVH) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,549 shares of the technology company’s stock, valued at approximately $213,000.

A number of other institutional investors have also added to or reduced their stakes in the company. UBS Asset Management Americas Inc. acquired a new position in Evolent Health during the first quarter worth approximately $13,393,000. Tygh Capital Management Inc. raised its position in Evolent Health by 199.8% in the first quarter. Tygh Capital Management Inc. now owns 314,942 shares of the technology company’s stock valued at $7,023,000 after buying an additional 209,876 shares in the last quarter. State Street Corp raised its position in Evolent Health by 5.2% in the fourth quarter. State Street Corp now owns 250,000 shares of the technology company’s stock valued at $3,699,000 after buying an additional 12,339 shares in the last quarter. Russell Investments Group Ltd. raised its position in Evolent Health by 111.6% in the first quarter. Russell Investments Group Ltd. now owns 168,409 shares of the technology company’s stock valued at $3,755,000 after buying an additional 88,830 shares in the last quarter. Finally, American Century Companies Inc. raised its position in Evolent Health by 5.2% in the first quarter. American Century Companies Inc. now owns 162,116 shares of the technology company’s stock valued at $3,615,000 after buying an additional 8,020 shares in the last quarter. 68.08% of the stock is currently owned by institutional investors and hedge funds.

Evolent Health, Inc (NYSE EVH) opened at 17.05 on Friday. The firm’s market cap is $1.12 billion. Evolent Health, Inc has a 12 month low of $14.50 and a 12 month high of $27.50. The stock has a 50 day moving average of $23.54 and a 200-day moving average of $22.66.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Monday, August 7th. The technology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $107.30 million for the quarter, compared to analysts’ expectations of $104.45 million. Evolent Health had a negative return on equity of 6.44% and a negative net margin of 17.57%. The company’s revenue for the quarter was up 89.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.20) EPS. Equities research analysts predict that Evolent Health, Inc will post ($0.42) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.com-unik.info/2017/08/19/parametric-portfolio-associates-llc-purchases-shares-of-9549-evolent-health-inc-nyseevh-updated.html.

Several equities analysts have commented on EVH shares. Zacks Investment Research lowered shares of Evolent Health from a “buy” rating to a “hold” rating in a report on Thursday, May 4th. Cowen and Company reaffirmed an “outperform” rating and set a $35.00 price target on shares of Evolent Health in a report on Wednesday, June 28th. BidaskClub lowered shares of Evolent Health from a “buy” rating to a “hold” rating in a report on Monday, July 31st. ValuEngine lowered shares of Evolent Health from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Finally, Robert W. Baird began coverage on shares of Evolent Health in a report on Thursday, June 1st. They set an “outperform” rating and a $30.00 price target on the stock. Three analysts have rated the stock with a sell rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Evolent Health has a consensus rating of “Buy” and an average target price of $29.90.

In other news, CFO Nicholas Mcgrane sold 10,495 shares of the business’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $26.95, for a total transaction of $282,840.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Kenneth A. Samet sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $25.75, for a total value of $103,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,398,253 shares of company stock worth $113,721,009. Corporate insiders own 8.79% of the company’s stock.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Institutional Ownership by Quarter for Evolent Health (NYSE:EVH)

What are top analysts saying about Evolent Health Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Evolent Health Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit